A Phase 2 interventional study of Follitropin delta in Infertility, Intrauterine Insemination and Reproduction, sponsored by Clinique Ovo. Completed at 1 site in Canada. Open to female participants aged 18 Years to 42 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-13.
Sponsored by Clinique Ovo · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.
Among the 13 studies testing follitropin delta in Infertility, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 5 in phase 2, and was the 7th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18–38 · Women only
By country, each count listing its studies:
follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 42 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2020.
This study's enrollment of 110 is below the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 220 across the 13 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 4 most frequent:
Clinique Ovo is the lead sponsor of 36 studies on the registry; 1 is open to participants now.
20 studies in Infertility by Clinique Ovo: none open now, none under way, none of them phase 3. Of 18 finished, 0 (0%) have results posted.
Among the 20 studies in Infertility by Clinique Ovo, this one is the only one that started in 2020, is one of 2 in phase 2, and was the 12th registered.
Clinique Ovo’s Infertility studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing follitropin delta in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Clinique Ovo’s 20 in Infertility:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is intended for women undergoing their first cycle of 3 intrauterine inseminations. All 3 inseminations will be personalized by using algorithms to determine the dose of study medication.
Study medication dosage for the first insemination cycle will be based on the woman's age as well as her Anti-Mullerian Hormone (AMH) levels.
Study medication dosage for the second and third insemination will depend on ovarian response (number of follicles) during previous insemination cycle and woman's age
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive a prescription for study medication Rekovelle (follitropin delta)
Drug: Follitropin delta
Study medication doses during all 3 insemination will be personalized using a suggested algorithm
Also known as: Rekovelle
Ovarian response
Evaluate the dose-response Relationship of Rekovelle with respect to ovarian response in participants undergoing controlled ovarian stimulation for intrauterine insemination
Time frame: 1 year
Pregnancy rate
Evaluate pregnancy rate 6-8 weeks after insemination by ultrasound
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2020 to primary completion in Jan 2021, 12 months.
Of 30 phase 2 interventional studies under Infertility, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin delta